Amphastar Pharmaceuticals, Inc. (AMPH) stock
Close on Nov 11, 2026Market cap $1.22BP/E 13.0Yield –
Amphastar Pharmaceuticals, Inc. grew revenue 3.1% to $745.79M over the twelve months to Sep 30, 2026. Operating income fell 6.8% to $139.74M, moving the operating margin from 20.7% to 18.7%. Free cash flow was $139.02M, up 22.7% from a year earlier. At the latest close the market valued the company at $1.22B, 13.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.22B
- P/E ratio
- 13.0
- Price to sales
- 1.63
- Price to book
- 1.49
- Dividend yield
- –
- Free cash flow yield
- 11.43%
Fundamentals
- Revenue
- $745.79M
- Net income
- $98.96M
- EPS, diluted
- $2.20
- Free cash flow
- $139.02M
- Book value per share
- $18.78
- Diluted shares
- 43M
Trading
- Next earnings
- Feb 25, 2027 (estimated, during market hours)
- Previous close
- $29.06
- Open
- $28.87
- Day's range
- $28.50 – $29.30
- Volume
- 497,666
- Average volume (20 days)
- 464,046
- Index membership
- S&P SmallCap 600, Russell 2000, Russell 3000
- Beta (5 years)
- 0.56
- 52-week range
- $16.64 – $31.00
- RSI (14 days)
- 63.2
- Volatility (1 year)
- 50.9%
- Relative volume
- 1.07×
- WACC
- 6.4%
On 2 of our idea lists: Buyback cannibals, Shareholder yield
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AMPH | S&P 500 | Difference | AMPH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +7.4% | -2.4% | +9.8 pts | ||
| 3 months | +40.1% | -1.2% | +41.2 pts | ||
| Year to date | +6.8% | +12.3% | −5.5 pts | ||
| 1 year | +5.3% | +12.4% | −7.1 pts | ||
| 3 years | -45.6% | +78.8% | −124.4 pts | -18.4% | +21.4% |
| 5 years | +35.0% | +75.2% | −40.1 pts | +6.2% | +11.9% |
| 10 years | +36.6% | +311.1% | −274.5 pts | +3.2% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Amphastar Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
About Amphastar Pharmaceuticals
Pharmaceutical Preparations
The company is a biopharmaceutical business that develops, manufactures, and commercializes injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredients. Its commercial portfolio includes over twenty-five prescription drugs and an over-the-counter asthma inhaler, Primatene MIST. Key offerings comprise BAQSIMI nasal powder for severe hypoglycemia, generic glucagon, epinephrine, lidocaine, enoxaparin, naloxone, and insulin active pharmaceutical ingredients. It also develops biosimilar insulin candidates and proprietary therapeutics. The company sells its products primarily to healthcare institutions, including hospitals, clinics, long-term care facilities, and medical offices, as well as to retail pharmacies through wholesale distributors and group purchasing organizations.
Company profile, executives and historyAmphastar Pharmaceuticals stock: common questions
What is Amphastar Pharmaceuticals's stock price?
AMPH closed at $28.60 on Nov 11, 2026, down 1.58% on the day. Over the past 52 weeks it traded between $16.64 and $31.00.
What is Amphastar Pharmaceuticals's market cap?
Amphastar Pharmaceuticals was worth $1.22B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AMPH's P/E ratio?
AMPH trades at 13.0 times earnings, based on diluted earnings per share of $2.20 over the twelve months to Sep 30, 2026.
How much revenue does Amphastar Pharmaceuticals make?
Amphastar Pharmaceuticals reported revenue of $745.79M for the twelve months to Sep 30, 2026, up 3.1% from a year earlier.
Does Amphastar Pharmaceuticals pay a dividend?
No. Amphastar Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Amphastar Pharmaceuticals report earnings next?
Amphastar Pharmaceuticals is expected to report Q4 FY2026 results on Feb 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has AMPH stock performed over the past year?
Including dividends, AMPH returned +5.3% over the past year, against +12.4% for the S&P 500.
How many AMPH shares are sold short?
4M shares were sold short at the latest FINRA report, 16.34% of the float, or 11.3 days of average trading volume.
Who are Amphastar Pharmaceuticals's competitors?
Companies most similar to Amphastar Pharmaceuticals by business, industry and size include LQDA, ANIP, MNKD, AAPG, EBS.
See a number that looks wrong?